Alexios Matikas, Associate Professor of Oncology at Karolinska Institute, shared a paper he and his colleagues authored on LinkedIn:
“Trials on adjuvant endocrine therapy for luminal breast cancer agree on only one thing: that it improves patient outcome. But which is the optimal strategy? In our comprehensive network meta-analysis and analysis of reconstructed individual patient data, the third part of a collaboration between Karolinska Institutet and Vall d’Hebron Institute of Oncology (VHIO), published today at eClinicalMedicine – The Lancet Discovery Science (IF: 9.6) we aim to answer this question.
Thank you to all collaborators: Andri Papakonstantinou, Guillermo Villacampa, Víctor Navarro Garcés, Antonios Valachis, Mafalda Oliveira, Tomás Pascual Martínez.”
Adjuvant endocrine treatment strategies for non-metastatic breast cancer: a network meta-analysis
Authors: Andri Papakonstantinou et al.
